Anti-beta Amyloid 1-28抗体

Cat. Number:

Anti-beta Amyloid 1-28抗体XY-0105M

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

The cerebral and Anti-beta Amyloid 1-28抗体vascular plaques associated with Alzheimer's disease (AD) are mainly composed of amyloid beta peptides (Ab). Ab is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Ab [1-40], Ab [1-42], and Ab [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Ab [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Ab antibodies and peptides have been developed as tools for elucidating the biology of AD.

Also known as:

Anti-beta Amyloid 1-28抗体beta Amyloid(1-28); beta-Amyloid 1-28; beta-Amyloid 1-28; Amyloid 1-28; A4; AAA; ABETA; ABPP; AD1; P3(40); P3(42); Alzheimers Disease Amyloid Protein; Amyloid B; Amyloid Beta A4 Protein Precursor; Amyloid Beta; Amyloid of Aging and Alzheimer Disease; APP; APPI; B Amyloid; Beta APP; Cerebral Vascular Amyloid Peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A beta; A4_HUMAN.

Specificity:

Storage:

Shipped at 4℃, Anti-beta Amyloid 1-28抗体Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal workingAnti-beta Amyloid 1-28抗体 dilutions must be determined by the end user.